Healthcare professionals and patients should understand three critical developments in hepatitis B therapeutics. First, GlaxoSmithKline’s bepirovirsen has achieved a 18% functional cure rate in phase 2 trials, compared to just 1% with conventional therapy—a transformative improvement for patients requiring more effective treatment options.
Second, bepirovirsen employs novel antisense RNA technology to directly target hepatitis B viral replication, representing a mechanistic departure from existing nucleoside analogues that primarily suppress rather than eliminate the virus. This approach offers potential for more durable viral suppression and improved patient outcomes.
Third, phase 3 trials are launching within 12 months, indicating a relatively rapid progression toward potential clinical availability. For the 296 million individuals with chronic hepatitis B worldwide, these developments signify meaningful progress toward more curative therapeutic options that could fundamentally alter disease management paradigms.
Read the full article on GMJ Newsroom.
Was this article helpful?
